- Home
- RDZN vs IXHL Comparison
RDZN vs IXHL Comparison
Compare RDZN & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RDZN | IXHL |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.7M | 97.6M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | RDZN | IXHL |
|---|---|---|
| Price | $1.30 | $3.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 164.7K | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | $33.77 | N/A |
| Revenue Next Year | $51.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $0.11 |
| 52 Week High | $2.56 | $5.17 |
Technical Indicators
Market Signals| Indicator | RDZN | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 82.81 |
| Support Level | $1.26 | $0.31 |
| Resistance Level | $1.45 | $5.17 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | 0.02 | 0.39 |
| Stochastic Oscillator | 47.04 | 73.70 |
Price Performance
Historical ComparisonAbout RDZN Roadzen Inc.
Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.